Wegovy HD 7.2 mg reaches US pharmacies at $399 a month for self-pay patients

Novo Nordisk's higher-dose Wegovy HD (semaglutide) injection 7.2 mg is reaching US pharmacies in April 2026 in a single-dose pen, listed at $399 a month for self-paying patients ^[1][2][3]. The FDA approved the 7.2 mg dose on March 19, 2026 ^[1][3].

The approval covers long-term reduction of excess body weight in adults with obesity, or with overweight plus at least one weight-related condition ^[1]. The label says patients must have tolerated the 2.4 mg dose for at least four weeks and have additional weight reduction be clinically indicated before moving up ^[3]. The 7.2 mg dose is also approved in the EU and UK ^[1]. It was the fourth product cleared under the FDA's Commissioner's National Priority Voucher pilot program and the first GLP-1 receptor agonist in that program, according to AJMC ^[1].

In the 72-week STEP UP trial, 1,407 adults with obesity and without diabetes were randomly assigned to 7.2 mg, 2.4 mg or placebo, all with lifestyle intervention ^[1][3]. Novo Nordisk reported average weight loss of about 19% (18.8%) in the 7.2 mg group when all patients were counted whether or not they stayed on treatment, compared with about 16% (15.5%) at 2.4 mg and about 4% (3.9%) for placebo ^[3]. In an analysis that assumed everyone stayed on treatment, the company reported about 21% (20.7%) at 7.2 mg versus about 18% (17.5%) at 2.4 mg and about 2% (2.4%) for placebo ^[3]. AJMC reported the 7.2 mg arm as 18.7% versus 3.9% for placebo, a slightly different figure for the higher dose ^[1].

Just under one in three participants on 7.2 mg — 31.2% — lost 25% or more of their body weight, compared with 15.3% on 2.4 mg and 0% on placebo ^[3]. In the 7.2 mg group, 89% lost at least 5% of body weight versus 38% on placebo, from a mean starting weight of 248 pounds ^[3].

A separate trial, STEP UP T2D, enrolled about 512 adults with obesity and type 2 diabetes. There, the 7.2 mg dose produced 13.2% mean weight loss versus placebo, and 21.3% of patients lost at least 20% of body weight ^[1].

Tolerability tracked earlier semaglutide studies, with gastrointestinal problems the most common side effects ^[1]. The label lists nausea, vomiting, dysesthesia, constipation, abdominal pain, fatigue, headache, dizziness, hair loss and flatulence as the most common adverse reactions with Wegovy HD ^[3]. Altered skin sensation was reported more often at the higher dose: 22% at 7.2 mg versus 6% at 2.4 mg and 0.3% on placebo in STEP UP ^[3], and 18.9% versus 4.9% and 0% in STEP UP T2D ^[1].

Novo Nordisk's price guide lists the Wegovy HD pen at $399 a month for self-pay, compared with $349 a month for the standard Wegovy pen doses ^[2]. A limited-time offer gives new patients $199 a month for the first two months at the 0.25 mg and 0.5 mg doses through December 31, 2026, after which those doses move to $349 a month; the $399 HD price is not part of that introductory offer ^[2]. With commercial insurance, the copay card lists as little as $25 a month, capped at $100 in savings per month, with government beneficiaries excluded ^[2]. Novo Nordisk says it can change or cancel the program at any time ^[2]. The drug will be sold through more than 70,000 US pharmacies — including CVS and Costco — as well as select telehealth providers, NovoCare Pharmacy and GoodRx ^[3].

Why it matters for patients

For people who have taken 2.4 mg semaglutide but have not reached their weight goals, the 7.2 mg pen adds an option within the same drug rather than a switch to a different medication, and AJMC notes it may offer a step-up before consideration of bariatric surgery ^[1]. The difference in average weight loss between the two doses was about 3 percentage points in the trial's main comparison, while the share of people reaching 25% weight loss roughly doubled ^[3].

The self-pay price is $50 a month higher than the standard Wegovy pen doses ^[2]. Coverage details for the 7.2 mg pen have not been disclosed; Novo Nordisk said information on coverage and savings options for eligible patients would be available at launch ^[3]. Whether insurers will require prior authorization or step therapy for the higher dose has not been reported.

Altered skin sensation, including sensitive skin and tingling, was several times more common at 7.2 mg than at 2.4 mg in both trials ^[1][3]. The label's four-week tolerance requirement applies to the 2.4 mg dose; the trial figures describe what was reported on 7.2 mg itself.

What happens next

Wegovy HD is expected in US pharmacies in April 2026 through all channels where Wegovy is currently sold ^[1][3]. Novo Nordisk says additional coverage and savings information will be available when the product launches ^[3]. The new-patient offer of $199 a month for the 0.25 mg and 0.5 mg doses runs through December 31, 2026 ^[2].